EUVIMEDEUVIMED entdecken
Open Access

COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization

Jennifer R Head, Philip A Collender, Tomás M León, Lauren A White, Sohil R Sud, Simon K Camponuri, Vivian Lee, Joseph A Lewnard, Justin V Remais

JAMA Network Open · 2024

DOI: 10.1001/jamanetworkopen.2024.7822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Jennifer R Head und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, University of Michigan, Ann Arbor. Hauptthemen laut MEDLINE: COVID-19, Hospitalization, COVID-19 Vaccines, SARS-CoV-2. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance A SARS-CoV-2 vaccine was approved for adolescents aged 12 to 15 years on May 10, 2021, with approval for younger age groups following thereafter. The population level impact of the pediatric COVID-19 vaccination program has not yet been established.

Objective

To identify whether California's pediatric COVID-19 immunization program was associated with changes in pediatric COVID-19 incidence and hospitalizations. Design, Setting, and Participants A case series on COVID-19 vaccination including children aged 6 months to 15 years was conducted in California. Data were obtained on COVID-19 cases in California between April 1, 2020, and February 27, 2023. Exposure Postvaccination evaluation periods spanned 141 days (June 10 to October 29, 2021) for adolescents aged 12 to 15 years, 199 days (November 29, 2021, to June 17, 2022) for children aged 5 to 11 years, and 225 days (July 17, 2022, to February 27, 2023) for those aged 6 to 59 months. During these periods, statewide vaccine coverage reached 53.5% among adolescents aged 12 to 15 years, 34.8% among children aged 5 to 11 years, and 7.9% among those aged 6 to 59 months. Main Outcomes and Measures Age-stepped implementation of COVID-19 vaccination was used to compare observed county-level incidence and hospitalization rates during periods when each age group became vaccine eligible to counterfactual rates predicted from observations among other age groups. COVID-19 case and hospitalization data were obtained from the California reportable disease surveillance system.

Results

Between April 1, 2020, and February 27, 2023, a total of 3 913 063 pediatric COVID-19 cases and 12 740 hospitalizations were reported in California. Reductions of 146 210 cases (95% prediction interval [PI], 136 056-158 948) were estimated among adolescents aged 12 to 15 years, corresponding to a 37.1% (35.5%-39.1%) reduction from counterfactual predictions. Reductions of 230 134 (200 170-265 149) cases were estimated among children aged 5 to 11 years, corresponding to a 23.7% (20.6%-27.3%) reduction from counterfactual predictions. No evidence of reductions in COVID-19 cases statewide were found among children aged 6 to 59 months (estimated averted cases, −259; 95% PI, −1938 to 1019), although low transmission during the evaluation period may have limited the ability to do so. An estimated 168 hospitalizations (95% PI, 42-324) were averted among children aged 6 to 59 months, corresponding to a 24.4% (95% PI, 6.1%-47.1%) reduction. In meta-analyses, county-level vaccination coverage was associated with averted cases for all age groups. Despite low vaccination coverage, pediatric COVID-19 immunization in California averted 376 085 (95% PI, 348 355-417 328) reported cases and 273 (95% PI, 77-605) hospitalizations among children aged 6 months to 15 years over approximately 4 to 7 months following vaccination availability. Conclusions and Relevance The findings of this case series analysis of 3 913 063 cases suggest reduced pediatric SARS-CoV-2 transmission following immunization. These results support the use of COVID-19 vaccines to reduce COVID-19 incidence and hospitalization in pediatric populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HospitalizationCOVID-19 VaccinesSARS-CoV-2HumansChildAdolescentIncidenceChild, PreschoolCaliforniaInfantFemaleMaleVaccinationImmunization Programs

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Epidemiology, University of Michigan, Ann Arbor.
  • Insitute for Global Change Biology, University of Michigan, Ann Arbor.
  • Division of Environmental Health Sciences, University of California, Berkeley.
  • California Department of Public Health, Richmond.
  • College of Letters and Sciences, University of California, Berkeley.
  • Division of Epidemiology, University of California, Berkeley.

Förderung

  • NIAID NIH HHS

Zitieren

APA

Head, J. R., Collender, P. A., León, T. M., White, L. A., Sud, S. R., Camponuri, S. K., Lee, V., Lewnard, J. A., & Remais, J. V. (2024). COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.7822

Vancouver

Head JR, Collender PA, León TM, White LA, Sud SR, Camponuri SK, et al. COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.7822

BibTeX
@article{Head2024,
  author = {Head, Jennifer R and Collender, Philip A and León, Tomás M and White, Lauren A and Sud, Sohil R and Camponuri, Simon K and Lee, Vivian and Lewnard, Joseph A and Remais, Justin V},
  title = {COVID-19 Vaccination and Incidence of Pediatric SARS-CoV-2 Infection and Hospitalization},
  journal = {JAMA Network Open},
  year = {2024},
  doi = {10.1001/jamanetworkopen.2024.7822}
}
Kostenlos starten →